Biotechnology · Nasdaq

REGNRegeneron Pharmaceuticals, Inc.

Last close
$955.47 +0.5%
52-week range
$591.52 to $991.73
Market cap
$90.2B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$14.3B
+1% vs FY24
Net income
$4.50B
+2% vs FY24
Free cash flow
$4.08B
+11% vs FY24
Net cash
$6.62B
Cash $8.61B, debt $1.99B

Stock price

+156% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 2 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
21.1x
8.8x49.3x
60th percentile, above its median of 18.9x
Price / sales
5.3x
4.0x10.9x
28th percentile, below its median of 6.5x
EV / EBITDA
15.4x
7.4x30.6x
42nd percentile, below its median of 16.2x
Price / free cash flow
23.6x
8.6x64.2x
50th percentile, above its median of 23.2x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
21.1x
Earnings yield
4.7%
Price / sales
5.3x
Price / book
2.7x
Price / operating cash flow
18.6x
EV / EBITDA
15.4x
EV / sales
4.9x
Free cash flow yield
4.2%

Profitability

Gross margin
n/aNot reported
Operating margin
28.8%
Net margin
28.5%
Return on equity
14.4%
Return on capital
11.6%

Growth per year

Revenue, 3 years
+5.6%
Revenue, 5 years
+11.0%
Revenue, 9 years
+12.8%
EPS, 3 years
+2.8%

Balance sheet

Cash and investments
$9.30B
Total debt
$1.99B
Net cash
$7.31B
Debt / equity
0.06x
Current ratio
3.35x

Shares and dividend

Shares outstanding
94.4M
Share count, 5 years
-5.6%
Beta, 1 year
0.34
Dividend yield
0.4%
Dividend per share, TTM
$3.70
Payout ratio
8.0%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $5.12B
RevenueNet income
Gross profitLatest quarter $1.44B
EBITDALatest quarter $2.17B
Margins95 / 40 / 38%
GrossOperatingNet
Earnings per shareLatest quarter $18.45
Cash flowLatest quarter $1.78B
OperatingCapexFree
Cash vs debtLatest quarter $9.30B
Cash and investmentsTotal debt
P/E historyNow 21.1x
P/E, median 18.9x dashed
P/S historyNow 5.3x
P/S, median 6.5x dashed

Where the revenue comes from

Product went from 57% to 44% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Collaboration RevenueProductProduct and Service OtherOther Products
FY22
40%57%
$12.2B
FY23
42%54%
$13.1B
FY24
43%54%
$14.2B
FY25
51%44%
$14.3B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Collaboration Revenue$7.33B51.1%+21%
Product$6.31B44.0%-17%
Product and Service Other$703M4.9%+36%
Other Products$10.1M0.1%n/a

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
REGN Regeneron Pharmaceuticals, Inc. $90.2B +19% 28.8%21.1x5.3x 60th percentile

The company

Sector
Health Care
Industry
Biotechnology
Founded
1988
Headquarters
Tarrytown, NY
Fiscal year ends
December
Website
regeneron.com

What it does

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about REGN.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,026 active funds. Crowd level: quiet.

Open the Smart money tab